REG - Cizzle Biotechnology - Subscription to raise £350,000

Cizzle Biotechnology HoldingsAnnouncement

12/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230612:nRSL3252Ca&default-theme=true

RNS Number : 3252C  Cizzle Biotechnology Holdings PLC  12 June 2023

12 June 2023

 

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR TO
THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR
ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA ("EEA") (OTHER THAN ANY MEMBER
STATE OF THE EEA WHERE SECURITIES MAY BE LAWFULLY MARKETED) OR ANY OTHER
JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. THE
INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER TO
ISSUE OR SELL, OR ANY SOLICITATION OF ANY OFFER TO SUBSCRIBE OR PURCHASE, ANY
INVESTMENTS IN ANY JURISDICTION.

This announcement is an advertisement for the purposes of the Prospectus
Regulation Rules of the UK Financial Conduct Authority ("FCA") and is not a
prospectus. This announcement does not constitute or form part of, and should
not be construed as, an offer for sale or subscription of, or solicitation of
any offer to subscribe for or to acquire, any ordinary shares in Cizzle
Biotechnology Holdings PLC in any jurisdiction, including in or into the
United States, Canada, Australia, the Republic of South Africa or Japan.
Investors should not subscribe for or purchase any ordinary shares referred to
in this announcement except on the basis of information in the prospectus (the
"Prospectus") in its final form, published by Cizzle Biotechnology Holdings
PLC in connection with the proposed admission of the Subscription Shares to
the Standard Listing segment of London Stock Exchange plc's Main Market for
listed securities.

This announcement contains Inside Information for the purposes of article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018 ("UK MAR"). In addition, market soundings
(as defined in UK MAR) were taken in respect of certain of the matters
contained within this announcement, with the result that certain persons
became aware of Inside Information (as defined under UK MAR). Upon the
publication of this announcement via a Regulatory Information Service, those
persons that received Inside Information in a market sounding are no longer in
possession of such Inside Information, which is now considered to be in the
public domain.

 

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology", "Cizzle", the "Company", or the "Group")

Subscription to raise £350,000

Variation to £500,000 Loan Facility

 

Cizzle Biotechnology, the UK-based diagnostics developer, is pleased to
announce that it has conditionally raised gross proceeds of £350,000 (before
expenses of £17,500) by way of the issue of 16,666,667 new Ordinary Shares at
2.1p per share ("Issue Price") with new and existing Investors (the
"Subscription").

Use of Proceeds

·     The funds raised from the Subscription will be used, inter alia, to
provide working capital for the Company's strategy and to:

o  Continue development of a laboratory-developed test ("LDT") accredited
service for the early detection of lung cancer.

o  Progress the Company's proprietary CIZ1B biomarker blood test through to
UKCA, CE marking and/or FDA 510(k) clearance and;

o  Commence development of its Point of Care rapid test for use in doctors'
offices and pharmacies.

 

Variation to £500,000 Loan Facility

Pursuant to its facility agreement with E3 Fund SP (the "Investor") entered
into on 20 September 2022 ("Facility") and amended on 21 April 2023, the
Company and the Investor are pleased to announce they have agreed to vary the
terms of the Facility to enable the Subscription to proceed at a premium to
the fixed repayment price of the Facility of 1.8p per share.

The Facility has been extended until 8 December 2024 and will be drawable in
tranches of not less than £100,000 as requested by the Company or the
Investor. The first drawdown will be made available to the Company following
Shareholder Approval at the Company's next General Meeting to allot a further
23,809,524 new Ordinary Shares. Repayment of the Facility is to be by way of
issue and allotment of new Ordinary Shares in the capital of the Company at a
new fixed price equal to the Issue Price of 2.1p per share ("Facility
Shares").

 

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

"Cizzle continues to make excellent progress in developing its laboratory test
for CIZ1B. Through refining our test we are now at a stage when we can
commence work on our point of care test for use in doctors' offices and
healthcare outlets such as pharmacies. The funds raised from the Subscription
and converting the Facility in full will provide continued momentum in
bringing our proprietary novel technologies for detecting lung and other
cancers at an early stage to thereby potentially preventing suffering and
saving many lives.

 

Background

The Group is developing a blood test for the early detection of lung cancer.
Its proof-of-concept prototype test is based on the ability to measure a
stable blood plasma biomarker, a variant of CIZ1. CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early-stage lung cancer.

Published research led by Professor Coverley has demonstrated that CIZ1B can
be measured with high sensitivity via an ELISA process, which should allow for
testing in a high-throughput, hospital-friendly format. The Directors believe
that this development overcomes an important barrier to further clinical
development and the application of this blood test for the early detection of
lung cancer, which is essential to improve a patient's chance of survival.

In addition to implementing a strategy to develop a regulatory approved
commercial, diagnostic laboratory immunoassay for early-stage lung cancer, the
Group has broadened its interests to include the detection of a range of other
early-stage cancers.  While the first product is expected to be a laboratory
based test the company is now ready to commence development of a point of care
test provided by a primary health care provider.

Admission of the New Ordinary Shares

Application will be made for the 16,666,667 Subscription Shares to be admitted
to the Official List of the FCA by means of a standard listing under Chapter
14 of the Listing Rules ("Standard Listing") and to trading on the Main Market
of the London Stock Exchange. It is expected that Admission will become
effective and that unconditional dealings will commence on the London Stock
Exchange at 8.00 a.m. on 20 June 2023. The New Ordinary Shares will be
eligible for CREST settlement and settlement of transactions in the
Subscription Shares may take place within the CREST system if a Shareholder so
wishes. The Subscription Shares will represent 5.0% of the Enlarged Share
Capital.

The New Ordinary Shares will not be dealt on any other recognised investment
exchange and no application has been or is being made for the Subscription
Shares to be admitted to any other such exchange.

 

Total Voting Rights

Following Admission of the New Ordinary Shares, the total number of Ordinary
Shares in issue will be 330,781,120 each with equal voting rights.  The
Company does not hold any rights in treasury.  The total voting rights figure
can be used by Shareholders as the denominator for the calculations by which
they will determine whether they are required to notify their interest in, or
a change of their interest in, the Company under the Disclosure Guidance and
Transparency Rules of the Financial Conduct Authority.

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 33285656
 John Depasquale
 Alex Brearley

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe          cizzle@investor-focus.co.uk
 Florence Chandler

 

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer.  Cizzle Biotechnology is a spin- out from the University of
York, founded in 2006 around the work of Professor Coverley and colleagues.
Its proof-of-concept prototype test is based on the ability to detect a stable
plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com/)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFBMLTMTABBIJ